Previous 10 | Next 10 |
NOVATO, Calif., May 10, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Shalini Sharp, the company’s Chief Financial...
The following slide deck was published by Ultragenyx Pharmaceutical Inc. in conjunction with this Read more ...
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2019 Results Earnings Conference Call May 06, 2019, 05:00 PM ET Company Participants Danielle Keatley - Senior Director, IR and Corporate Communications Emil Kakkis - CEO and President Vlad Hogenhuis - COO Shalini Sharp - CFO Camille B...
Ultragenyx Pharmaceutical (NASDAQ: RARE ): Q1 GAAP EPS of -$1.82 misses by $0.18 . More news on: Ultragenyx Pharmaceutical Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Strong Crysvita® (burosumab) Launch Continues with Approximately 730 Patients on Reimbursed Commercial Therapy in the United States NOVATO, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the developmen...
NOVATO, Calif., April 30, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Monday, May 6, ...
Source: Shutterstock The stock market has continued to edge higher and the two major indexes, the Nasdaq ( QQQ ) and S&P 500 ( SPY ), touched the all-time high milestone last week. The steady gain reflects a diminishing concern relating to the pace of a global economic slowdown, as m...
The following slide deck was published by Ultragenyx Pharmaceutical Inc. in conjunction with this Read more ...
The FDA grants Fast Track and Rare Pediatric Disease designations for Ultragenyx's (NASDAQ: RARE ) UX007 for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), a group of inherited diseases in which the body is unable to convert long-chain fatty acids into energy. ...
NOVATO, Calif., April 16, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has g...
News, Short Squeeze, Breakout and More Instantly...
Ultragenyx Pharmaceutical Inc. Company Name:
RARE Stock Symbol:
NASDAQ Market:
Ultragenyx Pharmaceutical Inc. Website:
NOVATO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5...
NOVATO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the company will share the latest clinical data, regulatory progress and program next steps for GTX-102, its investigational antisense oligonucleotide for Angelman syndrome, on Wed...
2024-07-24 04:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...